The relationship of mismatch negativity to quantitative EEG and morphological findings in schizophrenia

Kirino, Eiji; Inoue, Reiichi

doi:10.1016/s0022-3956(99)00012-6

Cited by 28 publications

(20 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Like PPI, MMN is presumed to reflect a predominantly automatic, preconscious process-in this case, one of detecting a 'mismatch' between the deviant stimulus and a sensory-memory trace (Näätänen et al, 1989). MMN amplitude reduction in schizophrenia was reported over 20 years ago (Shelley et al, 1991) with subsequent studies consistently identifying deficits in chronic and unmedicated patients Bodatsch et al, 2011;Brockhaus-Dumke et al, 2005;Light & Braff, 2005;Kirino & Inoue 1999;Catts et al, 1995).…”

Section: Introductionmentioning

confidence: 99%

Memantine Effects On Sensorimotor Gating and Mismatch Negativity in Patients with Chronic Psychosis

Swerdlow

Bhakta

Chou

et al. 2015

Neuropsychopharmacol

View full text Add to dashboard Cite

Patients with chronic psychotic disorders (CPD) exhibit deficient sensorimotor gating (measured by prepulse inhibition (PPI) of startle) and mismatch negativity (MMN). In healthy subjects (HS), N-methyl-D-aspartate (NMDA) antagonists like memantine and ketamine increase PPI, and under some conditions, memantine enhances MMN; these findings present a challenge to understanding the basis for deficient PPI and MMN in psychotic disorders, as reduced NMDA activity is implicated in the pathogenesis of these disorders. Here we assessed for the first time the effects of memantine on PPI and MMN in CPD subjects. Baseline PPI was measured in HS and patients with a diagnosis of schizophrenia or schizoaffective disorder, depressed type. Subjects (total n = 84) were then tested twice, in a double-blind crossover design, comparing either: (1) placebo vs 10 mg of memantine or (2) placebo vs 20 mg memantine. Tests included measures of acoustic startle magnitude and habituation, PPI, MMN, autonomic indices, and subjective self-rating scales. Memantine (20 mg) significantly enhanced PPI in CPD subjects, and enhanced MMN across subject groups. These effects on PPI were age dependent and most evident in older CPD patients, whereas those on MMN were most evident in younger subjects. The lower dose (10 mg) either had no detectable effect or tended to degrade these measures. The NMDA antagonist, memantine, has dose-dependent effects on preconscious, automatic measures of sensorimotor gating and auditory sensory processing that are associated with enhanced cognition and function in CPD patients. Ongoing studies will determine whether these memantine-induced changes predict acute pro-cognitive or otherwise clinically beneficial effects in CPD patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Memantine Effects On Sensorimotor Gating and Mismatch Negativity in Patients with Chronic Psychosis

Swerdlow

Bhakta

Chou

et al. 2015

Neuropsychopharmacol

View full text Add to dashboard Cite

show abstract

“…It is necessary to present repeated standard stimuli (23). Presentation of a single stimulus is not sufficient to generate MMN.…”

Section: What Is "Mismatch Negativity" (Mmn)?mentioning

confidence: 99%

Mismatch Negativity in Patients with Schizophrenia

Urban

Kremláček

Libiger

2007

Acta Med. (Hradec Kralove, Czech Repub.)

View full text Add to dashboard Cite

Summary:Cognitive deficit is considered to be a part of core dysfuncions in schizophrenia. It is associated with social impairment and influences the long-term course of the disorder. In addition to neuropsychological methods, event-related potentials can be used to study cognitive functions. In patients with schizophrenia an association was found between amplitude changes in slow negative component of evoked responses and infrequent deviations in a series of uniform stimuli. This amplitude change is known as "mismatch negativity" (MMN). It is supposed to be independent of the focused attention and effort that otherwise interfere with neuropsychological testing. Recently accumulated knowledge on MMN as a possible preattentive measure of cognition supports its potential significance for neuropsychological assessment. It may be helpful in more precise diagnosis and functional evaluation of schizophrenia.

show abstract

“…In den meisten Studien konnte eine verminderte MMN bei schizophren Erkrankten belegt werden (Übersicht in ⊡ Tabelle 1), lediglich 5 der mittlerweile über 40 Studien zeigten keine signifikante Verminderung der MMN [18,23,24,36,37]. Da die Messwerte von Patienten und Kontrollen insgesamt stark überlappen, darf eine gewisse Anzahl von nicht positiven Befunden aus rein statistischen Gründen nicht verwundern.…”

Section: Befunde Zur Mmn In Der Schizophrenieforschungunclassified

“…In den meisten Studien konnte eine verminderte MMN bei schizophren Erkrankten belegt werden (Übersicht in ⊡ Tabelle 1), lediglich 5 der mittlerweile über 40 Studien zeigten keine signifikante Verminderung der MMN [18,23,24,36,37] [45], sodass man davon ausgehen muss, dass zumindest Teile der Gedächtnisspur auch länger als 10-15 s verfügbar sind.…”

Section: Befunde Zur Mmn In Der Schizophrenieforschungunclassified

“…kürzerer Erkrankungsdauer eine Minderung der MMN feststellen zu können, ist geringer als bei Patienten mit schwererer/längerer Erkrankung. In 2 Studien, die keine Minderung der MMN in der Gruppe der Schizophrenen fanden, wiesen die Patienten eher leichtere Formen der Erkrankung auf[24,37]. Dies ist daraus zu entnehmen, dass in beiden Studien die Patienten 3 Monate ohne Medikation belassen werden konnten, sowie aus der Tatsache, dass bei Kirino und Inoue[24] trotz einer durchschnittlichen Erkrankungsdauer von 6,3 Jahren 20 der 30 Patienten zuvor nie mit Neuroleptika behandelt worden waren.…”

unclassified

See 1 more Smart Citation

Mismatch negativity in schizophrenia research

Rosburg

Kreitschmann-Andermahr

Sauer

2004

Nervenarzt

View full text Add to dashboard Cite

Mismatch negativity (MMN) represents an event-related component of the auditory evoked potentials at about 100-250 ms, evoked by discernible changes in an ongoing uniform acoustic stimulation. The current paper reviews all recently published MMN studies in the field of schizophrenia research. A reduced MMN in schizophrenic patients is found in the majority of the studies. This deficit is likely to be related to the disorder, since antipsychotic medication seems to have little influence on these results. Interestingly, a reduced MMN is also found in first-degree relatives of patients. Clear evidence for a hemispheric lateralization of the MMN reduction in schizophrenic patients is lacking. A hypofunction of the N-methyl-D-aspartate (NMDA) receptor is discussed as a possible explanation of this deficit.

show abstract

The relationship of mismatch negativity to quantitative EEG and morphological findings in schizophrenia

Cited by 28 publications

References 57 publications

Memantine Effects On Sensorimotor Gating and Mismatch Negativity in Patients with Chronic Psychosis

Memantine Effects On Sensorimotor Gating and Mismatch Negativity in Patients with Chronic Psychosis

Mismatch Negativity in Patients with Schizophrenia

Mismatch negativity in schizophrenia research

Contact Info

Product

Resources

About